
Concluding the sessions at #ASIPP2026, topics included brand development, risk reduction, novel non-opioid NaV1.8 pain signal inhibitor, audit and preauthorization burdens, and developments in chronic opioid therapy and THC products.
We hope to see you in Orlando for #ASIPP2027




English








































































